BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Top Story

Reata stopping bardoxolone trial

Reata Pharmaceuticals Inc. (Irving, Texas) is terminating the Phase III BEACON trial in Type II diabetics with chronic kidney disease (CKD) after seeing "excess serious adverse events and mortality" in patients receiving bardoxolone methyl. Reata and partner Abbott Laboratories (NYSE:ABT)...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >